AngioDynamics (NASDAQ:ANGO) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of AngioDynamics (NASDAQ:ANGO) in a research report report published on Friday morning, Benzinga reports. The firm currently has a $14.00 target price on the medical instruments supplier’s stock.

Separately, Canaccord Genuity Group reduced their price objective on shares of AngioDynamics from $18.00 to $13.00 and set a buy rating on the stock in a research note on Wednesday, July 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, AngioDynamics currently has a consensus rating of Moderate Buy and an average target price of $12.25.

AngioDynamics Trading Down 0.5 %

NASDAQ ANGO opened at $7.50 on Friday. The firm’s 50 day simple moving average is $7.49 and its 200 day simple moving average is $6.52. The firm has a market capitalization of $300.41 million, a price-to-earnings ratio of -1.55 and a beta of 0.65. AngioDynamics has a 1 year low of $5.26 and a 1 year high of $8.25.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.11. The business had revenue of $71.00 million during the quarter, compared to analysts’ expectations of $70.86 million. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The business’s revenue for the quarter was down 22.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.02 EPS. On average, equities research analysts forecast that AngioDynamics will post -0.41 earnings per share for the current year.

Institutional Trading of AngioDynamics

Several large investors have recently modified their holdings of the stock. Armistice Capital LLC bought a new stake in AngioDynamics in the fourth quarter valued at $6,272,000. Millennium Management LLC raised its stake in shares of AngioDynamics by 41.9% in the second quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock worth $10,850,000 after purchasing an additional 529,861 shares during the last quarter. Fund 1 Investments LLC purchased a new position in AngioDynamics during the 4th quarter worth $3,896,000. Western Standard LLC boosted its holdings in AngioDynamics by 878.5% during the first quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock worth $3,072,000 after purchasing an additional 469,906 shares during the last quarter. Finally, First Eagle Investment Management LLC purchased a new position in shares of AngioDynamics in the 2nd quarter worth approximately $1,321,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.